German biotech firm Ethris GmbH has added three new members to the Ethris board of directors: Leon Chen, venture partner with OrbiMed, Thomas Chalberg, COO of Oncorus, and Justin Duckworth, managing partner with HS Life Sciences.

Prior to joining OrbiMed, Chen co-founded KAI Pharmaceuticals, where he was responsible for research, intellectual property and business development before Amgen acquired KAI in 2012.

Chalberg, currently chief operating officer of Oncorus, an early-stage immuno-oncology company using oncolytic viruses for the treatment of glioblastoma and other malignancies. Previously, Chalberg founded and served as the CEO of Avalanche Biotechnologies, a developer of gene therapies for blinding diseases.

Duckworth, currently managing general partner at HS LifeSciences. Duckworth, who has spent the last 16 years working for venture capital funds within life sciences, previously was a partner at Nomura Phase4 Ventures in London, an investment advisor at HBM Partners in Zurich and a vice president in the Private Equity group of Dresdner Kleinwort Capital in London.

Topics